BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Full description

Bibliographic Details
Main Authors: Maria Stella Pennisi, Stefania Stella, Silvia Rita Vitale, Adriana Puma, Sandra Di Gregorio, Chiara Romano, Elena Tirrò, Michele Massimino, Agostino Antolino, Sergio Siragusa, Donato Mannina, Stefana Impera, Caterina Musolino, Giuseppe Mineo, Bruno Martino, Valentina Zammit, Francesco Di Raimondo, Livia Manzella, Fabio Stagno, Paolo Vigneri
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
Chronic Myeloid Leukemia
doubling-time
halving-time
tyrosine kinase inhibitors
BCR-ABL1/ABL1IS
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00764/full

Similar Items

Similar Items